MRgFUS in first-line management of low-risk prostate cancer


The London Health Sciences Center and the Lawson Clinical Research Institute in London, Ontario, Canada, have reported the first use of MRI-guided ultrasound ablation for the treatment of low-risk, prostate cancer.

Although the announcement from the two centers does not state this specifically, it appears that this technique is based on the use of InSightec’s ExAblate MRI-guided focused ultrasound surgery (MRgFUS) system. Information about a feasibility study using this technology for the treatment of low-risk prostate cancer can be found on the ClinicalTrials.gov web site.

One Response

  1. Please note that after careful research we have learned that this study does not, in fact, use the ExAblate technology. It uses a completely new device known as the Prostate Ablation Device: PAD-105 developed by a Toronto-based company called Profound Medical Inc..

    The summary of the trial protocol is available on the ClincialTrials.gov web site. Clinical experience with the application of this technology in man is currently extremely limited (one patient that we know of as of April 26, 2013).

    There is some (limited) animated informational material on the company’s web site about how this technology is supposed to work.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: